Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023
Eikichi Ihara1,2, Noriaki Manabe1, Hidenori Ohkubo1
1Guidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Digestion
|August 28, 2024
Summary
The Japan Gastroenterological Association
Area of Science:
- Gastroenterology
- Clinical Practice Guidelines
Background:
- Chronic diarrhea poses a significant clinical challenge globally.
- Existing guidelines require regular updates based on emerging evidence.
Purpose of the Study:
- To present the first version of the Japan Gastroenterological Association's clinical guidelines for chronic diarrhea (2023).
- To provide evidence-based recommendations for diagnosis and management.
Main Methods:
- Comprehensive review of the latest evidence on chronic diarrhea.
- Development of diagnostic and treatment flowcharts.
- Classification of chronic diarrhea based on etiology.
Main Results:
- Guidelines cover definition, classification, diagnosis, and treatment of chronic diarrhea.
- Initial treatment focuses on lifestyle, diet, probiotics, and anti-diarrheals.
- Evidence for other medications like 5HT3 antagonists and antibiotics is limited.
Conclusions:
- The 2023 JGA guidelines offer updated strategies for chronic diarrhea management.
- These guidelines are valuable for clinical practice in Japan and worldwide.
- Further research is needed to establish evidence for various therapeutic agents.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
328
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
328
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
01:17Chronic Bowel Disorders: Introduction
414
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
414
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
152
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
152
01:29Chronic Pancreatitis II: Collaborative Care
77
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
77
01:21Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146